Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients by Vera Bolanos, Elizabeth et al.
Clinical course and progression-free survival of adult intracranial and
spinal ependymoma patients
Elizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, Jimin Wu, Khalida Wani, Mary Jo Necesito-Reyes,
Howard Colman, Girish Dhall, Frank S. Lieberman, Philippe Metellus, Tom Mikkelsen, Antonio Omuro,
Sonia Partap, Michael Prados, H. Ian Robins, Riccardo Soffietti, Jing Wu, Mark R. Gilbert, and Terri S. Armstrong on
behalf of the CERN Foundation
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (E.V.-B., M.R.G.); Department of
Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of Biostatistics, The
University of Texas M.D. Anderson Cancer Center, Houston, Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of Neurosurgery, Huntsman Cancer Institute, University
of Utah, Salt Lake City, Utah (H.C.); Division of Hematology-Oncology, Children’s Hospital Los Angeles, Los Angeles, California (G.D.);
Departments of Neurology and Medicine (Medical Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
(F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France (P.M.);
Departments of Neurology & Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of Neurology, Memorial-Sloan
Kettering Cancer Center, New York, New York (A.O.); Department of Neurology, Stanford University & Lucile Packard Children’s
Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco,
California (M.P.); Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
(H.I.R.); Department of Neuroscience, University San Giovanni Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.); Department of Family Health, School of Nursing, The
University of Texas Health Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio
Corresponding Author: Elizabeth Vera-Bolanos, MS, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Unit 431,
P.O. Box 301402, Houston, TX 77230-1402 (evera@mdanderson.org).
Background. Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were
restricted to small sample sizes, often with patients at a specific institution.
Methods. Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all adults
aged 18 years or older at the time of diagnosis. Potential prognostic clinical factors identified on univariate analysis were included
in a multivariate Cox proportional hazards model with backwards selection to model progression-free survival.
Results. The 282 adult ependymoma patients were equally male and female with a mean age of 43 years (range, 18–80y) at
diagnosis. The majority were grade II (78%) with the tumor grade for 20 cases being reclassified on central review (half to higher
grade). Tumor locations were spine (46%), infratentorial (35%), and supratentorial (19%). Tumor recurrence occurred in 26% (n¼
74) of patients with a median time to progression of 14 years. A multivariate Cox proportional hazards model identified supra-
tentorial location (P, .01), grade III (anaplastic; P, .01), and subtotal resection, followed or not by radiation (P, .01), as signifi-
cantly increasing risk of early progression.
Conclusions. We report findings from an ongoing, multicenter collaboration from a collection of clinically annotated adult epen-
dymoma tumor samples demonstrating distinct predictors of progression-free survival. This unique resource provides the oppor-
tunity to better define the clinical course of ependymoma for clinical and translational studies.
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Ependymoma is a rare tumor that accounts for 2%–3% of all
primary central nervous system tumors.1,2 The World Health
Organization (WHO) grade classification system provides 3
grades of ependymoma with the most malignant being grade
III and entitled anaplastic ependymoma.3,4 Ependymomas
occur in both the pediatric and adult populations and occur
in both the brain and spine. They can also appear, rarely, out-
side the central nervous system.5,6 Due to its rarity, research
has mainly included only small numbers of samples from spe-
cific institutions with limited treatment and disease course in-
formation.7,8 Researchers exploring the established databases,
such as the Surveillance Epidemiology and End Results (SEER)
and the Central Brain Tumor Registry of the United States
(CBTRUS), have reported on the incidence and survival of epen-
dymoma patients,9 –13 but these reports are limited by data
quality, particularly accuracy of pathological diagnosis and ex-
tent of information regarding treatment. Review of the reported
literature to date has shown the extent of surgery, tumor loca-
tion, and tumor grade to be important to progression-free sur-
vival (PFS) in adult patients based on these small studies.2,14,15
To address the limitations of previous studies, the Collabora-
tive Ependymoma Research Network (CERN Foundation)16 de-
veloped a multi-institutional, clinically annotated tissue
repository in September 2009. It was developed to study the
clinical course of patients with ependymoma frommultiple insti-
tutions around the world, to identify clinically relevant molecular
markers that define molecular subtypes of ependymoma, and
to correlate these clinical and molecular factors with patient
outcome. The purpose of this report is to further define the clin-
ical and demographic factors associated with PFS in adult pa-
tients with ependymoma involving the brain and spine.
Methods
The CERN Ependymoma Correlative Tissue Repository was ap-
proved by Institutional Review Boards or their equivalents at
each of the participating centers. Any patient with an ependy-
moma in the brain or spine may be registered to the study. All
registered participants must have a paraffin tissue block with at
least 1 cm2 of tumor available for central review. All samples un-
derwent central review (by KA) to confirm diagnosis and tumor
grade. Once the diagnosis of ependymoma was confirmed, the
clinical history of the participant was collected including: (i)
tumor characteristics: location, grade; (ii) diagnosis details: extent
of initial resection (as described in operative reports and postop-
erative imaging), previousmisdiagnoses, other cancers; (iii) treat-
ment history: number of surgeries, radiation and chemotherapy
treatments and their types; and (iv) outcome information: pro-
gression/recurrence status and details and current vital status.
In order to have sufficient outcome data, participants with spinal
ependymoma were required to have had at least 4 years of
follow-up from diagnosis available to be eligible, unless the pa-
tient had a progression, recurrence, or death before 4 years.7,11
Participants aged 18 years and older at diagnosis were classified
as adults, as has been the standard in other reports.
Statistical Methods
All statistical analyses were performed on IBM SPSS Statistics
Version 19.17 Descriptive statistics were used for the frequency
of participant characteristics. Chi-square tests revealed associ-
ations between variables. In order to interpret the effect of age
in a more clinically relevant manner, age at diagnosis was di-
chotomized into 2 groups: younger and older than the median
age. PFS was calculated from the date of diagnosis to the first
tumor recurrence or the last follow-up date or date of death in
the absence of documented progression. Kaplan-Meier curves
were used to estimate the PFS. Log-rank tests were used to
determine significant differences in survival distributions
among groups. A multivariate Cox proportional hazards
model was fitted to identify the best prognostic factors of
shorter progression-free times. Variables with P, .05 were con-
sidered significantly relevant. Hazard ratios with corresponding
95% confidence intervals were calculated. Any variable that
was identified as a potential prognostic factor in univariate
analysis was included in the multivariate step. The variables
of interest were age at diagnosis (dichotomized younger or
older than sample median age), tumor grade by WHO classifi-
cation3 (I, II, III), tumor location (supratentorial, infratentorial,
or spine), and initial treatment regimen as determined by the
individual collaborating sites and according to study definitions
(gross total resection followed by observation [GTR], subtotal
resection followed by observation [STR], gross total resection
followed by radiation [GTR+ radiation], and biopsy/subtotal re-
section followed by radiation [STR+ radiation]).
Results
At the time of this analysis, 19 medical institutions were partic-
ipating in the study (16 in the United States, 2 in Europe, and 1
in Canada). Tumor tissue from 674 patients (including 360
adult patients) had undergone central review to confirm eligi-
bility. Two hundred eighty-two adult patients had clinically an-
notated tumor samples available for the present analysis.
Seventy-eight patients were found to be ineligible, with the pri-
mary reason being insufficient tumor tissue remaining in the
block for inclusion in the central repository. Ten patients were
found to have a different nonependymoma glial tumor after
the central review (see Supplementary material, Fig. S1).
Sample Characteristics
The 282 participants were equally male and female (51% vs
49%) with most being white non-Hispanic (86%). The median
age at diagnosis was 43 years (mean, 44y; range, 18–80y).
All 3 levels of the WHO grade classification were represented,
with grade II being the most common (78%). All grade I tu-
mors were myxopapillary ependymomas. During the central re-
view, the tumor grade was reclassified for 20 participants (7%)
with 11 moving to a higher grade. The reclassified tumor grade
was used in the analysis for these 20 participants. As expected,
the spine was the most common tumor location (46%), with
most in the cervical spine (33%). Twenty-one participants
(7%) had originally received a misdiagnosis, with their tumor
more frequently being called an astrocytoma (n¼ 9) (see Sup-
plementary material, Table S1). Participants were diagnosed
with ependymoma between 1972 and 2011, with available
follow-up from diagnosis ranging from zero to 27 years.
Table 1 further describes the participant sample.
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In terms of treatment, most participants underwent a GTR
followed by observation (57%). Radiation was given after
both subtotal resections (STR+ radiation¼ 20%) and gross
total resections (GTR+ radiation¼ 11%). For those who did re-
ceive radiation, it was most frequently conventional (external
beam) radiation (77%) to the involved field (77%), and only
8% received craniospinal radiation treatment. Only 10 partici-
pants received chemotherapy along with or closely following
their radiation treatment, and this was most commonly an
alkylating chemotherapy agent (70%). Table 1 details the clin-
ical characteristics.
Progression-free Survival
Twenty-six percent of participants had at least 1 recurrence or
progression, while 6% had at least 3 recurrences or progres-
sions. The majority of the recurrences occurred in the same lo-
cation as the original tumor (65%). A variety of treatments
Table 1. Sample characteristics and clinical details by tumor location




Spine n¼ 129 (46%)
Age at diagnosis, y
Mean (SD) 44 (15) 38 (13) 47 (14) 44 (15)
Range 18–80 18–65 21–75 18–80
Sex, n (%)
Male 143 (51) 28 (53) 53 (53) 62 (48)
Female 139 (49) 25 (47) 47 (47) 67 (52)
Ethnicity, n (%)
White non-Hispanic 242 (86) 49 (93) 85 (85) 108 (84)
Hispanic 15 (5) 2 (4) 3 (3) 10 (8)
Black 12 (4) 2 (4) 7 (7) 3 (2)
Asian 4 (1) 0 1 (1) 3 (2)
Unknown 9 (3) 0 4 (4) 5 (4)
Tumor grade, n (%)
I 30 (11) 0 (0) 0 30 (23)
II 221 (78) 32 (60) 93 (93) 96 (74)
III 31 (11) 21 (40) 7 (7) 3 (2)
Initial treatmenta, n (%)
GTR 161 (57) 15 (28) 51 (51) 95 (74)
STR 35 (12) 6 (11) 16 (16) 13 (10)
STR+ radiation 55 (20) 14 (26) 23 (23) 18 (14)
GTR+ radiation 31 (11) 18 (34) 10 (10) 3 (2)
Initial radiation method, n (%)
Conventional 66 (77) 26 (81) 23 (70) 17 (81)
IMRT 13 (15) 5 (16) 7 (21) 1 (5)
Radiosurgery 1 (1) 0 1 (3) 0
Missing 6 (7) 1 (3) 2 (6) 3 (14)
Initial Chemotherapyb, n (%) 10 (4) n (%) 7 (13) 1 (1) 2 (2)
Initial chemotherapy agents
Alkylating 7 (70) 6 (86) 0 1 (50)
ICE variation 2 (20) 1 (14) 0 1 (50)
Missing 1 (10) 0 1 (100) 0
Initial chemotherapy cycles
Median 6 4 – 9
Range 3–12 3–6 – 6–12
Median survival Not reached 7.8 Not reached Not reached
5-year survival Rate 87% 62% 85% 97%
5-year PFS Rate 77% 38% 78% 87%
Abbreviations: GTR, gross total resection followed by observation; GTR+ radiation, gross total resection followed by radiation; STR, subtotal
resection followed by observation; STR+ radiation, subtotal resection followed by radiation.
aInitial Treatment Variable is categorized as gross total resection followed by observation, subtotal resection followed by observation, subtotal
resection followed by radiation, and gross total resection followed by radiation.
bChemotherapy either with or following radiation.
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were used at the time of the first recurrence, with tumor resec-
tion being the most common (64%). Radiation treatment was
then administered after surgery in 22% of participants, and 7%
had subsequent chemotherapy. Table 2 details the recurrence
or progression specifics.
Median time to recurrence was 14 years for the sample as a
whole (range, 0.1–27.3y; 95% CI, 10.1–17.9). A log-rank test
revealed a significant difference in the PFS among the 3
tumor locations (x2¼ 46.4, P, .01). Kaplan-Meier curves esti-
mated the median time to progression at 3.9 years for the
supratentorial brain region (95% CI, 2.1–5.7) and 12.3 years
for the infratentorial brain region (95% CI, 9.1–15.4). A median
time was not reached for participants with a spine location;
however, 59% did not have a progression at 15.8 years.
When reported by tumor grade, grade III had the shortest
progression-free time, with a median of 2.3 years (95% CI,
1.2–3.5) (x2¼ 33.7, P, .01). There was also a significant differ-
ence in PFS according to initial treatment (x2¼ 19.9, P, .01).
Participants who underwent a subtotal resection, followed or
not by radiation, had a shorter progression-free time compared
with those who underwent a gross total resection, followed or
not by radiation. Finally, participants aged 43 years or younger
at diagnosis had a shorter progression-free time (median¼
13.4y; 95% CI, 10.6–16.2) than those aged 44 years and
older (median not reached). Figs. 1 and 2 display the PFS distri-
butions by variables of interest.
Table 2. Recurrence/progression specifics by tumor location
All (n¼ 282) Supratentorial Brain n¼ 53 (19) Infratentorial Brain n¼ 100 (35) Spine n¼ 129 (46)
Number of progressions, n (%)
None 208 (74) 26 (49) 74 (74) 108 (84)
1 46 (16) 11 (21) 19 (19) 16 (12)
2 10 (4) 5 (9) 5 (5) 0
≥3 18 (6) 11 (21) 2 (2) 5 (4)
Location, n (%)
Same as original 48 (65) 19 (70) 15 (58) 14 (67)
Different from original 12 (16) 3 (11) 6 (23) 3 (14)
Original plus additional 8 (11) 3 (11) 3 (12) 2 (10)
Unknown site 6 (8) 2 (7) 2 (8) 2 (10)
Treatment at first recurrence, n (%)
None 6 (8) 1 (4) 5 (19)
Surgery only 26 (35) 7 (26) 8 (31) 11 (52)
Radiation only 12 (16) 5 (19) 4 (15) 3 (14)
Chemotherapy only 6 (8) 3 (11) 1 (4) 2 (10)
Surgery and radiation 16 (22) 7 (26) 8 (31) 1 (5)
Surgery and chemotherapy 5 (7) 3 (11) 0 2 (10)
Other combinations 3 (4) 1 (4) 0 2 (10)
Fig. 1. Progression-free survival distributions by tumor characteristics. Caption: Progression-free survival distributions according to tumor location
(A) and tumor grade (B).
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Prognostic Factors for Shorter Progression-free Survival
A multivariate Cox proportional hazards model for PFS was fit-
ted using the following variables (based on univariate analysis):
tumor location, tumor grade, age, and initial treatment. A back-
ward stepwise selection revealed that tumor location, tumor
grade, and initial treatment all contributed significantly to
PFS. As seen in Table 3, participants with infratentorial tumors
or spine tumors were less likely to progress than those with
supratentorial tumors (hazard ratio [HR]¼ 0.33; 95% CI,
0.18–0.63; P, .01 and HR¼ 0.15; 95% CI, 0.07–0.31; P,
0.01, respectively). Tumor grade was also associated with out-
come; the diagnosis of a grade III tumor raised a participant’s
risk of progression when compared with a grade II tumor (HR¼
3.00; 95% CI, 1.45–6.07; P, .01). There was no difference in
PFS between grade I and grade II tumors (P¼ .19). Lastly, hav-
ing undergone only a biopsy or subtotal resection either alone
or followed by radiation increased the hazard of tumor progres-
sion or recurrence when compared with GTR (HR¼ 2.61; 95%
CI, 1.27–5.36; P, .01 and HR¼ 2.44; 95% CI, 1.36–4.36; P,
.01, respectively). Participants with GTR alone did as well as
those with GTR+ radiation (P, .27).
Because recent findings suggest that histological features
and specific molecular profiles (for subgroups of supra- and
infratentorial tumors) differ according to tumor location,18 a
separatemultivariate Cox proportional hazard model was fitted
for each of the 3 tumor locations. In the supratentorial brain
region, only initial treatment significantly contributed to PFS.
Participants who underwent STR+ radiation had a higher risk
of progression than those who only underwent GTR (HR ¼
5.38; 95% CI, 1.78–16.26; P, .01). Although, participants
with grade III supratentorial tumors showed a trend towards
having a shorter progression-free time than those with grade
I tumors, this effect did not reach significance (P, .09).
In the infratentorial brain region, no participants who under-
went GTR+ radiation had any progression. Therefore, we uti-
lized the Firth penalized method to fit the Cox proportional
hazard model.19 It showed that tumor grade and initial treat-
ment were significantly associated with PFS. Adults with grade
III infratentorial tumors had a higher risk for progression than
those with grade II infratentorial tumor (HR¼ 7.30; 95% CI,
1.30–29.34; P, .03). Participants who underwent GTR, STR,
or STR+ radiation also had higher risks of progression than
those who underwent a gross total resection followed by radi-
ation. (HR¼ 12.80; 95% CI, 1.50–1690.44; P, .01; HR¼ 34.37;
95% CI, 3.69–4658.06; P, .01; HR¼ 12.12; 95% CI, 1.32–
1627.69; P, .03, respectively). The confidence intervals for
the HRs are very wide; however, for such complete separation
of data (ie, all events occurred in one group). Heinze and
Schemper (2001) showed that the inference based on the
Firth penalized method is generally valid, although some cau-
tion should be executed when interpreting the confidence
intervals.19
In the spine region, initial treatment contributed signifi-
cantly to PFS. The hazard for progression increased more for
spine participants who underwent STR+ radiation than for
those who underwent GTR (HR¼ 5.01; 95% CI, 1.84–13.69;
P, .01). There was no difference in PFS between spine partici-
pants who underwent STR and those who underwent STR+ ra-
diation (HR¼ 0.31; 95% CI, 0.07–1.42; P¼ .13; data not
shown) or between spine participants with GTR and GTR+ radi-
ation (P, .2). Table 4 presents the prognostic factors by tumor
location.
Discussion
The data analyzed were generated from the CERN Ependy-
moma Correlative Tissue Repository, a collaborative multicen-
ter project designed to study the clinical course of patients
with ependymoma and its impact on survival. In this prelimi-
nary analysis, PFS was impacted by tumor grade, tumor loca-
tion, and initial treatment.
As previously reported, grade II ependymomas are the most
prevalent, and grade III tumors have the worst overall progno-
sis,2,7,11,13 particularly in both brain regions. However, our study
demonstrated that the grade I myxopapillary ependymoma,
which is traditionally considered to be a benign tumor, did
Fig. 2. Progression-free survival distributions by age at diagnosis (A) and initial treatment (B).
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not have a better outcome than the grade II ependymoma.18
There is ongoing debate in neuropathology on the use of histo-
logical features to grade ependymoma, whether myxopapillary
ependymoma may actually be a distinct disease, and how to
integrate the current WHO grading system with findings from
molecular studies.4,18,20 – 24 Furthermore, there is also the
issue of misdiagnosis. In the present study, 7% of participants
had an initial nonependymoma diagnosis that was later reclas-
sified as ependymoma, but other studies have reported misdi-
agnosis to be as high as 15%.7 These reports, coupled with our
findings regarding the lack of correlation of grade I and II tu-
mors with outcomes, lend support for the need for molecular
classification of these tumors to further refine tumor grade.
Tumor location was also associated with PFS. While previous
studies typically focused on ependymomas from a specific lo-
cation,8,9,14,25,26 our sample size was large enough to include
both brain and spine participants. Our results support the pre-
vious findings that intracranial ependymoma has an overall
worse prognosis compared with spinal cord tumors.2,7,11,13 In
addition, we were able to analyze the comparative risk of a
supratentorial location to a spine location or an infratentorial
location, with supratentorial location being associated with
shorter progression-free time then the other locations.
PFS was also associated with treatment at diagnosis. Extent
of initial surgery impacted PFS, with less than a gross total re-
section increasing the risk of early progression for all 3 regions,
thus supporting previous reports.14,15 Radiation at the time of
diagnosis was found to be beneficial for PFS (with a longer
progression-free time) in the infratentorial brain region. None
of the participants with infratentorial tumors who received ra-
diation after their initial gross total resection had a progression
or recurrence. This is consistent with other studies that strongly
support the utility of postoperative radiation, specifically for
infratentorial ependymoma regardless of the extent of resec-
tion.27 There were no obvious clinical or demographic charac-
teristics (such as tumor grade or age) of these 10 participants
that made them distinct from the remainder of the group.
Future development of molecular diagnostics and innovative
imaging may uncover additional characteristics that cannot
be ascribed from a retrospective analysis. For participants
with either a supratentorial or spine ependymoma, radiation
following a subtotal resection shortened PFS when compared
with a gross total resection only. However, it did not make a dif-
ference when compared with participants who also had a sub-
total resection but no radiation. This may reflect the variability
of the clinical decision-making process in which radiation is
often reserved for those with an incomplete resection and/or
higher tumor grade. The number of high-grade tumors in the
spine and supratentorial region was relatively small, and this
may account for the wide variance of outcomes and lack of sig-
nificance on multivariate analysis. Iqbal and Lewis summarized
the lack of consensus among researchers regarding the effect
of initial radiation treatment on outcome,2 as some studies
have shown it to be beneficial15 while others have not.9,14,28
The CERN Ependymoma Correlative Tissue Repository repre-
sents a large international collaboration designed to collect
clinically annotated tumor tissues from patients with ependy-
moma. This effort has been very successful in providing mate-
rials necessary for understanding the clinical outcomes as well
as molecular and pathological correlations as shown by recent
publications by Wani et al22 and Raghunathan et al.18 These
studies have provided important insights into the clinical course
and biology of ependymomas. There are, however, some limi-
tations to the interpretation of these data. The study is retro-
spective in nature, and most of the analyses are limited to
PFS given the overall long survival with ependymoma. For ex-
ample, in the patient population analyzed in the current
study only 49 had died at the time of the analysis. Such a
small number of deaths would yield inaccurate survival esti-
mates and thus were not included as part of this analysis.
Also, because the participating centers are all tertiary and aca-
demic institutions, there may be a bias in the referral pattern of
patients included in the study. However, this is balanced with
the inclusion of data from a multi-institutional, international
Table 3. Multivariate analysis of progression-free survival
Predictor Variable HR 95% CI P value Median PFS (years)
Age at diagnosisa 44 and older 1 Not reached
43 and younger 1.22 0.74–2.02 .428 13.4
Location* Supratentorial 1 3.9
Infratentorial 0.33 0.18–0.63 .001 12.3
Spine 0.15 0.07–0.31 ,.001 Not reached
Tumor grade* Grade II 1 15.8
Grade I 1.90 0.73–4.96 .189 Not reached
Grade III 3.00 1.45–6.07 .003 2.3
Initial treatment*,b GTR 1 Not reached
STR 2.61 1.27–5.36 .009 14
STR+ radiation 2.44 1.36–4.36 .003 11.3
GTR+ radiation 0.62 0.27–1.45 .271 10.8
Abbreviations: CI, confidence interval; GTR+ radiation, gross total resection followed by radiation; HR, hazard ratio; STR, subtotal resection followed
by observation; STR+ radiation, subtotal resection followed by radiation.
aBased on median age.
bInitial treatment variable is categorized as gross total resection followed by observation.
*Significant at P, .05.
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dataset. Furthermore, our data collection period included tran-
sitions in available technologies and treatments. While these
changes may impact the results, the impact would be minimal
because only 2 participants were diagnosed before 1980. Last-
ly, study procedures did not include a central imaging review.
All clinical data were determined and provided by the individual
participating centers based on their review of the medical re-
cord. Despite these limitations, this ependymoma repository
represents the largest clinically annotated ependymoma repos-
itory in the world. It presents an outstanding opportunity to ex-
plore the clinical course and molecular evolution of
ependymoma to both improve our understanding of the dis-
ease and ultimately identify molecular subtypes distinguish-
able by molecular biomarkers, which will lead to improved
and individualized patient treatment.
The importance of this ependymoma tumor tissue reposito-
ry is further underscored by the recent seminal discoveries
within the subtypes of supratentorial and infratentorial epen-
dymomas. A unique fusion, C11orf-RELA, was recently de-
scribed in a subset of patients with supratentorial
ependymoma.29 This molecular change results in the constitu-
tive activation of the NFKB pathway, is distinct from the tumors
without the fusion, and may provide a unique therapeutic tar-
get. Additionally, subsets of posterior fossa tumors were re-
cently found to be distinguishable from others by a
hypermethylated state of the CPG-islands (CIMP). As with the
supratentorial tumors, the CIMP status may provide a specific
therapeutic target.30 These discoveries are currently undergo-
ing extensive evaluation utilizing the clinically annotated re-
source provided by the ependymoma repository. Based on
these results and recent advancements in molecular classifica-
tion, we can explore associations between subgroups, extent of
resection, and impact of additional therapies, such as radiation,
on the likelihood of tumor progression.
Table 4. Multivariate analysis of progression-free survival by tumor location
Predictor Variable HR 95% CI P value
Supratentorial brain
Age at diagnosisa ≥37 y 1
,36 y 0.61 0.26–1.44 .258
Tumor grade Grade II 1
Grade III 2.21 0.89–5.48 .086
Initial treatment*,b GTR 1
STR 1.49 0.17–12.75 .718
STR+ radiation 5.38 1.78–16.26 .003
GTR+ radiation 1.39 0.5–3.67 .506
Infratentorial brainc
Age at diagnosis ≥48 y 1
,47 y 1.47 0.62–3.79 .384
Tumor grade* Grade II 1
Grade III 7.30 1.30–29.34 .027
Initial treatment*,b GTR+ radiation 1
GTR 12.80 1.50–1690.44 .014
STR 34.37 3.69–4658.06 ,.001
STR+ radiation 12.12 1.32–1627.69 .023
Spine
Age at diagnosis ≥45 y 1
≤44 y 2.93 0.95–9.05 .061
Tumor grade Grade II 1
Grade I 1.19 0.43–3.29 .742
Grade III 1.94 0.39–9.64 .416
Initial treatment*,b GTR 1
STR 1.54 0.32–7.55 .592
STR+ radiation 5.01 1.84–13.69 .002
GTR+ radiation 3.84 0.46–32.10 .215
Abbreviations: CI, confidence interval; GTR, Gross total resection followed by observation; GTR+ radiation, gross total resection followed by
radiation; HR, hazard ratio; STR, subtotal resection followed by observation; STR+ radiation, subtotal resection followed by radiation.
aBased on median age.
bInitial treatment variable is categorized as gross total resection followed by observation, subtotal resection followed by observation, subtotal
resection followed by radiation, and gross total resection followed by radiation.
cwith Firth’s penalized method.
*Significant at P, .05.
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